Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + ipilimumab + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Nivolumab + ipilimumab + nab-paclitaxel** is a combination regimen consisting of:\n- **Nivolumab** (Opdivo): a monoclonal antibody targeting PD-1, functioning as an immune checkpoint inhibitor.\n- **Ipilimumab** (Yervoy): a monoclonal antibody targeting CTLA-4, functioning as an immune checkpoint inhibitor.\n- **Nab-paclitaxel** (Abraxane): a nanoparticle albumin-bound formulation of paclitaxel (a microtubule inhibitor), serving as a chemotherapeutic agent.\n\nThis combination is being investigated in clinical trials for advanced or metastatic tumors, including **ER+HER2- breast cancer** and **pancreatic cancer**, aiming to exploit the synergistic effects of checkpoint inhibitor immunotherapy and chemotherapy, which may enhance antitumor immune response and tumor cell death[1][4][5]. Nivolumab and ipilimumab restore and potentiate T-cell antitumor activity, while nab-paclitaxel promotes immunogenic cell death[1][4].
- Other names
- nivolumabipilimumabnab-paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on nivolumab + ipilimumab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + ipilimumab + nab-paclitaxel.